NeuroSense Therapeutics Ltd
NRSN
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
100% downsideOvervalued by 100% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.26 Million |
|---|---|
| Enterprise Value | $20.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.44 |
| Beta | 1.58 |
| Outstanding Shares | 25,402,000 |
Return
| Return on Equity | 555.00% |
|---|---|
| Return on Assets | -842.22% |
| Return on Invested Capital | 575.94% |
Valuation & Multiples
| P/E Ratio | -3.21 |
|---|---|
| PEG | -1.83 |
| Price to Sales | - |
| Price to Book Ratio | -0.78 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.36 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.49%▲ 0.13% |
|---|---|
| Total Invested | $286,654▲ 7.69% |
| Investors Holding | 130% |
ESG Score
No data
About NeuroSense Therapeutics Ltd
Relevant Senate Committees
Investigates issues like neurodegenerative diseases and drug pricing. As NeuroSense focuses on ALS (a disease often associated with aging populations), this committee's hearings pose significant headline and regulatory risk.
Oversees Medicare and Medicaid, which determine reimbursement rates and coverage for new drugs. Its decisions on healthcare taxation and trade also directly impact corporate valuations in the pharmaceutical sector.
Directly oversees the FDA and NIH. This committee controls the regulatory framework for drug approvals and clinical trials, which are the most critical factors for a biotech company like NeuroSense.